Cargando…

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

BACKGROUND: Patients with Crohn’s disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G(2) monoclonal antibody against mucosal addressin cell adhesion molecule-1, is a potential novel CD treatment. OPERA II, a multicenter, open-label, phase 2 extension...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Haens, Geert R, Reinisch, Walter, Lee, Scott D, Tarabar, Dino, Louis, Edouard, Kłopocka, Maria, Klaus, Jochen, Schreiber, Stefan, Il Park, Dong, Hébuterne, Xavier, Nagy, Peter, Cataldi, Fabio, Martin, Steven W, Nayak, Satyaprakash, Banerjee, Anindita, Gorelick, Kenneth J, Sandborn, William J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247846/ https://www.ncbi.nlm.nih.gov/pubmed/34427633 http://dx.doi.org/10.1093/ibd/izab215

Ejemplares similares

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
por: Reinisch, Walter, et al.
Publicado: (2021)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease
por: Wang, Yi, et al.
Publicado: (2020)

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study
por: Reinisch, Walter, et al.
Publicado: (2020)

The influence of afferent lymphatic vessel interruption on vascular addressin expression
Publicado: (1991)

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial
por: Reinisch, Walter, et al.
Publicado: (2017)

Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO
por: Weinstein, Aliyah M., et al.
Publicado: (2016)

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study
por: D’Haens, Geert, et al.
Publicado: (2018)

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
por: Saruta, Masayuki, et al.
Publicado: (2020)

An NKX-COUP-TFII morphogenetic code directs mucosal endothelial addressin expression
por: Dinh, Thanh Theresa, et al.
Publicado: (2022)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib
por: Reinisch, Walter, et al.
Publicado: (2022)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year
por: Gibson, Peter R, et al.
Publicado: (2016)

Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
por: Jharap, B., et al.
Publicado: (2015)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes
Publicado: (1988)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

CCNP security VPN 642-647 quick reference
por: Matei, Cristian
Publicado: (2011)

The role of Cysteine 6.47 in class A GPCRs
por: Olivella, Mireia, et al.
Publicado: (2013)

647. Diagnoses Associated with Temperature ≥104°F in Adults
por: Chi, Sharon, et al.
Publicado: (2019)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Dach1 transcription factor regulates the expression of peripheral node addressin and lymphocyte trafficking in lymph nodes
por: Shintani, Arisa, et al.
Publicado: (2022)

Tumor necrosis factor receptor regulation of peripheral node addressin biosynthetic components in tumor endothelial cells
por: Rodriguez, Anthony B., et al.
Publicado: (2022)

CCNP security VPN 642-647 official cert guide
por: Hooper, Howard
Publicado: (2012)

Withdrawn Paper: Molecules 2001, 6, 647-654 [1]
Publicado: (2003)

Role of miR-647 in human gastric cancer suppression
por: Cao, Wenlong, et al.
Publicado: (2017)

Spotlight on the Expanding Role of miR-647 in Human Cancers
por: Jalili, Mohammadmahdi, et al.
Publicado: (2023)

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
por: Marquès Camí, Miquel, et al.
Publicado: (2021)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Essential role of peripheral node addressin in lymphocyte homing to nasal-associated lymphoid tissues and allergic immune responses
por: Ohmichi, Yukari, et al.
Publicado: (2011)

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study
por: Steere, Boyd, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
por: D’Haens, Geert, et al.
Publicado: (2023)

647. Characterization and Development of Human Monoclonal Antibodies to Pneumococcal Serotype 3
por: Babb, Rachelle, et al.
Publicado: (2018)

MON-647 Mechanisms of Insulin Resistance in Skeletal Muscle in Women with PCOS
por: Moreno-Asso, Alba, et al.
Publicado: (2020)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

The human peripheral lymph node vascular addressin is a ligand for LECAM-1, the peripheral lymph node homing receptor
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_gcrqnpvgvbagmqdp9cv1cr50eo